Oncology Clinical Pharmacy Specialist & Educator National Institutes of Health
Lisa Cordes: No financial relationships to disclose
In patients with cancer, venous thromboembolism (VTE) is the second leading cause of death after disease progression. Historically, low-molecular-weight heparins have been the standard of care in ambulatory patients with cancer associated VTE, however recent guidelines and evidence have suggested a shift to direct oral anticoagulants. Attend this session to hear from an expert in the field about updates related to anticoagulation in cancer.
Analyze clinical practice guideline recommendations for anticoagulation in patients with cancer.
Evaluate the evidence related to anticoagulant use in patients with cancer.
Discuss safety considerations associated with anticoagulant use in patients with cancer.
Select the most appropriate anticoagulant for a patient with cancer, considering the clinical scenario.